Scoop: Roche scraps one of two schizophrenia PhII trials after failing the primary endpoint

Roche has terminated one of two Phase II trials testing its drug ralmitaront in patients with schizophrenia, the Big Pharma confirmed to Endpoints News.

The study was terminated last month, according to a June 22 update to the registry on Begun in September 2020, the trial was looking at...

Click to view original post